From Bi- to Trispecific Antibodies: Reimagining the Next Generation of ADCs

• Bi- and Tri-specific matrix screening rapidly identifies optimal antibody pairings
• B-Body bispecific and T-Body trispecific antibodies exhibited good killing from in vitro ADC assays across a diverse set of breast cancer cell lines
• Multi-target ADCs demonstrate broader and more durable tumor control in vivo, including in drug-resistant cell populations that evade monospecific therapy

Speakers:

Andrew Garfoot

Senior Scientist II

Invenra